US FDA Cancels Panel Review Of Two ‘Delinquent’ Cancer Drug Accelerated Approvals

 
• By Sue Sutter
  
Cancelled sign
Since October, the FDA has cancelled ODAC reviews of accelerated approval drugs Farydak, Marqibo and Pepaxto. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers